A Dose-Escalation Study of RO5083945 in Patients With Metastatic and/or Locally Advanced Malignant Epidermal Growth Factor Receptor (EGFR)+ Solid Tumors.

Inclusion Criteria

• •adult patients, \>=18 years of age;
• •centrally confirmed EGFR expression in tumor tissue;
• •radiologically measurable or clinically evaluable disease;
• •last dose of systemic anti-neoplastic therapy or radiotherapy \>=28 days prior to start of study;
• •histologically or cytologically confirmed advanced stage, primary or metastatic EGFR+ solid tumors (Part 1);
• •histologically or cytologically confirmed advanced stage, primary or metastatic EGFR+ and mutant KRAS colorectal cancer (Part 2);
• •not more than 2 previous cytotoxic regimens for metastatic disease (Part 2).